Stryker Corporation

New York Stock Exchange
Back to all articles
Somewhat Bearish -35

Stryker ABG II Hip Lawsuit: 2026 Settlement Update

Lawsuit AI-generated analysis

📉 Stryker paid an estimated $1.4 billion combined to resolve ABG II and Rejuvenate hip stem claims through a settlement program announced in November 2014.

⚖️ As of January 2026, only 36 cases remain pending in the federal MDL No. 13-2441 for the ABG II and Rejuvenate products, down from an original pool of 3,638 filed cases.

🔒 The settlement program covered patients who underwent revision surgery before November 3, 2014, with a later extension covering surgeries through December 19, 2016.

⚠️ Newer litigation involving the Tritanium Acetabular Shell remains active and unresolved as of January 2026, distinct from the settled ABG II cases.

🏛️ A separate MDL No. 2768 in Massachusetts involves Stryker's LFIT V40 femoral head component, with 62 cases remaining pending as of January 2026.

📅 The original recall for Rejuvenate and ABG II modular-neck hip stems occurred in 2012 due to corrosion issues at the modular neck junction.

💰 Average per-plaintiff payouts under the historic settlement were roughly $300,000, varying based on injury severity and documentation.

🚫 New claims for the ABG II and Rejuvenate products are generally not accepted under the original terms of the closed settlement fund.

🔍 Eligibility for the historic payout required patients to have undergone revision surgery tied to the device recall within specific time windows.

Risk Factors
  • Stryker faces ongoing legal exposure from unresolved Tritanium Acetabular Shell lawsuits filed since 2019, which allege device loosening causing pain and revision surgery needs.
  • As of January 2026, 36 cases remain pending in the ABG II and Rejuvenate federal MDL, representing a lingering legal liability despite the bulk of the $1.4 billion settlement being paid.
  • Stryker has separate pending litigation involving its LFIT V40 femoral head component with 62 cases remaining active in MDL No. 2768 as of January 2026.
Full Analysis
Stryker Corporation's ABG II and Rejuvenate hip stem litigation has largely concluded following a confirmed settlement program announced in November 2014. The company paid out an estimated $1.4 billion combined to resolve claims related to corrosion and fretting at the modular neck junction, with average payouts reaching roughly $300,000 per plaintiff for those requiring revision surgery before the program's expiration dates. As of January 2026, a small fraction of the original case volume remains active in the federal Multidistrict Litigation (MDL) No. 13-2441, with only 36 cases still pending out of an initial pool of 3,638. These remaining matters are being handled individually rather than through the mass settlement structure that closed years ago. The article distinguishes these resolved cases from newer, unresolved litigation involving Stryker's Tritanium Acetabular Shell and LFIT V40 femoral head components. While the ABG II and Rejuvenate issues are effectively settled, the Tritanium Acetabular Shell lawsuits filed since 2019 remain open with no settlement reached, representing a separate ongoing legal exposure for the company. Stryker's financial exposure is now primarily tied to these specific pending cases and new filings regarding different hip components. The text clarifies that eligibility for the historic $1.4 billion payout was strictly limited to patients who underwent revision surgery within specific windows, while current claims must be evaluated against the distinct timelines of the active MDLs.